ID   RK35
AC   CVCL_C3VG
DR   ABCD; ABCD_AI744
DR   Wikidata; Q116050176
RX   Patent=US9926368;
RX   PubMed=16837207;
CC   Group: Patented cell line.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized domagrozumab (PF-06252616) therapeutic antibody which was used in clinical trials for the treatment of Duchenne muscular dystrophy.
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; O14793; Human MSTN.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   Patent=US9926368;
RA   Walsh F.S., Zaleska M.M., Howland D.S., Tchistiakova L.G., Karim R.,
RA   Kelley P., Tan X.-Y., Kwak S.P., Pangalos M.N.;
RT   "Method for treating muscle wasting syndrome using antagonist antibodies
RT   against GDF-8.";
RL   Patent number US9926368, 27-Mar-2018.
//
RX   PubMed=16837207; DOI=10.1016/j.nbd.2006.05.009;
RA   Holzbaur E.L.F., Howland D.S., Weber N., Wallace K., She Y.-J.,
RA   Kwak S.P., Tchistiakova L.G., Murphy E., Hinson J., Karim R., Tan X.-Y.,
RA   Kelley P., McGill K.C., Williams G., Hobbs C., Doherty P.,
RA   Zaleska M.M., Pangalos M.N., Walsh F.S.;
RT   "Myostatin inhibition slows muscle atrophy in rodent models of
RT   amyotrophic lateral sclerosis.";
RL   Neurobiol. Dis. 23:697-707(2006).
//